A German research consortium led by Heinrich Heine University and partners secured €3.2 million from the Federal Ministry of Research to develop a DNAzyme‑based cancer therapy platform called 'DNAmazing.' The funding supports efforts to design catalytically active DNA sequences (DNAzymes) that target and cleave cancer‑relevant RNAs and to advance a lead candidate toward clinical testing. The project includes academic and industry collaborators—Pantherna Therapeutics for lipid nanoparticle delivery and BioSpring for oligonucleotide manufacturing—and will receive supplemental support from the Federal Agency for Breakthrough Innovation (SPRIN‑D). Investigators aim to commercialize the technology and spin out a company by the program’s end, moving toward first‑in‑human studies. Project leaders highlighted DNAzymes’ programmable catalytic mechanism and the funding’s role in closing translational gaps for oligonucleotide therapeutics.